Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

Ravichandran, 2021 CTRI/2021/05/033544

Indomethacin (n=103) vs. paracetamol (n=107)

randomized controlled trial   some concerns about risk of bias

Studied treatment

Indomethacin
Standard of care plus indomethacin 75mg (once a day for BMI<30, twice a day for BMI>30). A proton pump inhibitor was also added along with indomethacin.

Control treatment

Paracetamol
Standard of care plus paracetamol 650mg four times a day.

All patients in both groups received standard of care (doxycycline, ivermectin, vitamin C, zinc, cough syrup).

Patients

COVID-19 mild to moderate

Hospitalized adult patients (20-90), with positive RT-PCR, normal KFT, normal LFT, oxygen saturation 94% or more.

Method

Open-label.

Panimalar Medical College, Chennai, India.

Follow-up through a telephonic enquiry.

Remark